Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 May 17.
Published in final edited form as: Acta Biochim Pol. 2011 May 17;58(2):225–230.

Cyclic enkephalin-deltorphin hybrids containing a carbonyl bridge: structure and opioid activity

Małgorzata Ciszewska 1, Katarzyna Ruszczyńska 2, Marta Oleszczuk 3, Nga N Chung 4, Ewa Witkowska 1, Peter W Schiller 4, Jacek Wójcik 2, Jan Izdebski 1,
PMCID: PMC3229099  NIHMSID: NIHMS305326  PMID: 21584287

Abstract

Six hybrid N-ureidoethylamides of octapeptides in which an N-terminal cyclic structure related to enkephalin was elongated by a C-terminal fragment of deltorphin were synthesized on MBHA resin. The synthetic procedure involved deprotection of Boc groups with HCl/dioxane and cleavage of the peptide resin with 45 % TFA in DCM. d-Lys and d-Orn were incorporated in position 2, and Lys, Orn, Dab, or Dap in position 5. The side chains of the dibasic amino function were protected with the Fmoc group. This protection was removed by treatment with 55 % piperidine in DMF, and cyclization was achieved by treatment with bis-(4-nitrophenyl)carbonate. Using various combinations of dibasic amino acids, peptides containing a 17-, 18-, 19- or 20-membered ring structure were obtained. The peptides were tested in the guinea-pig ileum (GPI) and mouse vas deferens (MVD) assays. Diverse opioid activities were observed, depending on the size of the ring. Extension of the enkephalin sequence at the C-terminus by a deltorphin fragment resulted in a change of receptor selectivity in favor of the δ receptor. The conformational propensities of selected peptides were determined using the EDMC method in conjunction with data derived from NMR experiments carried out in water. This approach allowed proper examination of the dynamical behavior of these small peptides. The results were compared with those obtained earlier with corresponding N-(ureidoethyl)pentapeptide amides.

Keywords: cyclic opioid peptides, conformation, NMR, N-(ureidoethyl)amides, side-chain to side-chain cyclization, structure-activity relationship

Introduction

Endogenous opioid peptides, such as enkephalins, endorphins, deltorphins, dynorphins and endomorphins are involved in regulation of many biological processes, among them pain control. However, clinical utility as therapeutic analgesics is limited by their susceptibility to enzymatic degradation and several side effects. Biological activities of opioid peptides are mediated through three major opioid receptor types (μ, δ and χ) and the distinct structure of a peptide has an impact on the selectivity of receptor types and consequently on the activity profile.

The analgesic effect of the most effective therapeutic non-peptidic agent, morphine, is mediated through the μ opiate receptor. However, its clinical utility is limited by the side effects, such as respiratory depression and development of tolerance and dependence.

Enkephalins and other δ opiate receptor selective drugs share the morphin's analgesic effect, but have reduced negative properties: respiratory depression (Cheng et al., 1993; Su et al., 1998) and reveal minimal potential for the development of physical dependence (Cowan et al., 1988).

The development of new opioid peptides with increased selectivity for δ opioid receptor seems to be a good avenue to obtaining drugs that may produce only desired physiological responses. One of the methods that could allow reaching this goal is the design of conformationally restricted peptides. The most promising approach to obtaining a selective agonist is cyclization of a linear active peptide which can adopt a conformation able to interact preferentially with one receptor. This is also expected to increase the enzymatic stability and activity of the resulting cyclic peptide.

Peptides can be cyclized through formation of additional bonds, eg., disulfide, lactone, lactame or formation of bridges between two amino acid residues, eg., a carbonyl bridge or oligomethylene group (Davis, 2003; Janecka & Kruszynski, 2005). In several cases incorporation of cyclized opioid peptides has been shown to enhance selectivity for a distinct opioid receptor type. Further increase in selectivity of an active and selective cyclic peptide is also possible as demonstrated by replacement of cysteine by β,β-dimethylcysteine in an enkephalin analogue cyclized by formation of a disulfide bridge (Akiyama et al., 1985).

Attempts to increase selectivity of a cyclic peptide by synthesis of chimeric peptides have also been reported: -Val-Gly-NH2, which is a C-terminal fragment of deltorphin address sequence (-Val-Val-Gly-NH2), was added to the above-mentioned enkephalin analogs cyclized by formation of a disulfide bridge between two β,β-dimethylcysteine residues (Misicka et al., 1994).

Previously we described the synthesis, biological activity, and conformational analysis of several highly potent side-chain-to-side-chain cyclized analogs of enkephalin amides (H-Tyr-Gly-Gly-Phe-Met-NH2) in which Gly2 and Met5 were replaced by dibasic amino acids and cyclic structure was obtained by incorporation of side-chain amino groups into urea residue (Pawlak et al., 2001; Filip et al., 2005). Using the same synthetic procedure we obtained analogs of an N-terminal segment of deltorphin (H-Tyr-Gly-Phe Asp-) by introduction of dibasic amino acids in positions 2 and 4 (Filip et al., 2003). We also obtained N-(ureidoethyl)amides of enkephalin related to the cyclic amides studied earlier, using a convenient synthetic method developed in this laboratory (Ciszewska et al., 2009).

Most peptides of those three series showed very high potency both in the guinea-pig ileum (GPI) and mouse vas deferens (MVD) assays, which indicated a need to modify their structure to obtain more selective opiates. Addition of address sequence of deltorphin (-Val-Val-Gly-NH2) to the cyclic structure comprising positions 1-4 resulted in greatly increased δ selectivity. Several such peptides were a hundred times more active in the MVD assay than in the GPI assay (Zieleniak et al., 2008).

In this work we obtained six hybrid peptides containing a message sequence of enkephalin, restricted via a urea bridge as described above, and a C-terminal address of deltorphin. To facilitate the synthesis, the peptides were obtained in the form of N-(ureidoethyl)amides.

Materials and Methods

Peptide synthesis

General procedure. The p-nitrophe-noxycarbonyl derivative of Boc-diaminoethane was obtained as described earlier (Wiszniewska et al., 2005). This compound (0.401 g, 1.25 mmol) was coupled to the MBHA resin (0.25 meq/g, 1 % crosslink, 100–200 mesh) in DMF at 60°C for 48 days. The Boc group was removed by treatment with 15 % HCl/dioxane, then Boc-amino acids were successively attached using N,N′-diisopropylcarbodiimide as a coupling reagent and 15 %HCl/ dioxane for deprotection. The side chain amino function was protected by Fmoc group. The Tyr side chain was not protected. The peptidyl-resin was treated with 55 % piperidine in DMF with stirring for 50 min to remove the Fmoc groups and washed with DMF. To a stirred suspension of peptidyl-resin in DMF (200 ml) bis(p-nitro-phenyl)carbonate (0.76 g, 0.25 mmol) was added in portions (about 50 % + 25 % +12.5 % + 12.5 %) and stirring was continued for 7 days. DIPEA (0.065 g) was gradually added during this reaction. The peptide was cleaved off by treatment with 55 %TFA/DCM for 1 + 20 min. TFA was evaporated under reduced pressure and the residue was lyophilized. The yield of the crude product was 80–140 mg. The products were purified by semi-preparative reversed-phase high performance liquid chromatography using the solvent system: A: 0.05 % TFA in water, B: 60 % MeCN in A on a Vydac column (Nucleosil 300, C18, 5 μm, 10 × 250 mm), fow rate of 2 ml/ min, gradient B (15 % in 15 min, 15–30 % in 15 min, 30–45 % in 40 min). Fractions were analyzed on a Vertex Nucleosil-100 C18 column (4 × 250 mm, 5μm), flow rate 1 ml/min. For analysis, a linear gradient of 20–80 % B was used (1 ml/min, t = 15 min), detection at 220 nm. Fractions were pooled for maximum purity rather than yield. Homogeneous fractions containing one peak were combined and lyophilized. Structures were confrmed by ESI-MS mass spectrometry (Finningan MAT 95S spectrometer, Bremen, Germany). 1: M calcd. 965.5, obtained 988.6 (M+Na+); 2: M calcld. 979.5, obtained 1002.6 (M+Na+); 3: M calcld 993.4, obtained 1016.6 (M + Na+); 4: M calcld. 951.3, obtained 974.5 (M+Na+); 5: M calcld. 965.5, obtained 988.6 (M+Na+); 6: M calcd. 993.4 obtained 1016.4 (M+Na+). The structures of the peptides are presented in Fig. 1.

Figure 1. Structural formula of peptides: 1.

Figure 1

(d-Lys2, Dap5; m=4, n=1); 2 (d-Lys2, Dab5; m=4, n=2); 3 (d-Lys2, Orn5; m=4, n=3); 4 (d-Orn2, Dap5; m=3, n=1); 5 (d-Orn2, Dab5; m=3,n=2); 6 (d-Orn2, Lys5; m=3, n=4)

Bioassays

The guinea-pig ileum (GPI) assay (μ receptor-representative) (Paton, 1957) and the mouse vas deferens (MVD) assay (δ receptor-representative) (Henderson at al., 1972) were carried out as reported in detail elsewhere (Schiller et al., 1978; DiMaio &Schiller, 1980). A log dose-response curve was determined with [Leu5]-enkephalin as a standard for each ileum and vas preparation and the IC50 values of the compounds being tested were normalized according to a published procedure (Waterfield et al., 1979). The results are presented in Table 1.

Table 1. GPI and MVD assays of cyclic hybrid peptides.

PEPTIDE GPI MVD GPI/MVD

No. Ring size d-Daa2 Daa5 IC50[nM] Rel. potency IC50[nM]a Rel. potency IC50 ratio
1 18 Lys Dap 12.9 ± 1 19.0 ± 2 1.85 ± 0.1 6.15 ± 0.45 6.97
2 19 Lys Dab 47.5 ± 5 5.18 ± 0.5 16.9 ± 0.5 0.675 ± 0.019 2.81
3 20 Lys Orn 30.8 ± 1 7.98 ± 0.4 4.18 ± 5 2.73 ± 0.034 7.37
4 17 Orn Dap 76.9 ± 3 3.20 ± 0.1 18.5 ± 2 0.617 ± 0.058 4.16
5 18 Orn Dab 72.1 ± 6 3.41 ± 0.3 20.5 ± 4 0.555 ± 0.109 3.52
6 20 Orn Lys 71.3 ± 3 3.45 ± 0.2 14.5 ± 1 0.788 ± 0.078 4.92

[Leu5]enkephalin 246 ± 39 1 11.4 ± 1.1 1 21.6
a

Mean of 3-6 determinations ± SEM

NMR spectroscopy and theoretical analysis

The methodology used for generation and selection of conformations was previously described for oxytocin and arginine-vasopressin (Liwo et al., 1996). It was applied by us to one of the opioid peptides and described in details in this journal (Sidor et al., 1999) and by others to a number of compounds (Masman et al., 2006; 2008; Cohen et al., 2002). Subsequently we used this methodology with success in several studies of different opioid analogues (Pawlak et al., 2001; Filip et al., 2003; 2005; Ciszewska et al., 2009). In this paper NMR spectra of peptides 2, 3 and 4, which were suffciently soluble in water, were recorded on a Varian INOVA 400 MHz and/or a Varian Unity PLUS 500 MHz spectrometer at 25 °C in H2O/D2O (9 : 1, v/v). For 1D proton spectra 16k points were collected and a spectral width of 6 kHz was used. 2D experiments were measured collecting 2k points using 4.5 kHz spectral width in the proton direction and 256-point increments in the F1 direction. The same spectral width was applied in the F1 direction in homo-nuclear 2D spectra, whereas a width of 25 kHz and 2 kHz for carbon and for nitrogen, respectively, was used for hetero-nuclear correlations. A mixing time of 0.08 s was used in TOCSY measurements and 0.25 s in ROESY experiments. DSS was used as a reference external standard for proton, carbon and nitrogen dimensions (Wishart et al.,1995). Chemical shifts were assigned using TOCSY, COSY, HSQC [15N, 1H], and HSQC [13C, 1H] techniques (Aue et al., 1976; Braunschweiler & Ernst, 1983; Bothner-By et al., 1984; Bax & Davis, 1985a; Bax & Freeman, 1985b; Palmer III et. al., 1991; Kay et al., 1992) and they are available in Supplementary Materials at www.actabp.pl (Table 1S and 2S). 3JHαHN couplings were obtained from 1D 1H spectra and temperature co-efficients were determined with 1D 1H spectra recorded at: 6.8, 11.0, 15.5, 19.1 and 25.0 °C (see Table 3S in Supplementary Materials). Cross-peak volume calculations were done with the SPARKY program (www.cgl.ucsf.edu/home/sparky) using data from the ROESY spectra and are available in Supplementary Materials (Tables 4S, 5S and 6S).

Structures of each peptide were calculated using the EDMC method described by (Liwo et al., 1996), e.g., for each peptide starting from a conformation with random geometry its energy was minimized with the ECEPP/3 force field (Nemethy et al., 1992) and surface model SFROPT (Vila et al., 1991). Thus, the total conformational energy included a sum of terms: electrostatic, non-bonding, hydrogen-bond, torsional and terms accounting for the entropy for loop closing and solvation. The ϕ and ψ angels of the resulting geometry were further perturbed using the Monte Carlo method (Li & Scheraga, 1987) and after energy minimization the obtained conformation was compared with the previous one and accepted or discarded using a geometry and/or energy criterion. If the conformation was accepted the procedure was repeated.

The ensemble of resulting structures for each peptide was clustered into families using the program CLUST (Spath, 1980). Finally, theoretical NOESY spectra were generated for each family of structures with the program MORASS (Meadows, 1994) and statistical weights for each conformation were obtained by fitting a linear combination of generated spectra to the experimental data using the Marquardt method (Marquardt, 1963).

Results and Discussion

The synthesis was performed using a method based on the observation that N-ureidoethyl units could be obtained in the synthesis on MBHA resin by reaction of the resin with p-nitrophenyl carbonate of Boc-ethylen-ediamine and that the aminoethylurea unit was formed is stable during treatment with HCl/dioxane used for removal of the Boc group (Wiszniewska et al, 2005). d-Lys or d-Orn were incorporated in position 2, and Lys, Orn, Dab or Dap in position 5 of the peptide sequence using Boc-protected derivatives in the α-amino group and Fmoc protection at the side chain amino group. After removal of the Fmoc group by treatment with 55 % piperidine in DMF and cyclization in a reaction with bis-(4-nitrophenyl)carbonate the resulting peptide was cleaved from the resin by treatment with 45% TFA in DCM. The products were purified using semi-preparative RP-HPLC. Higher amounts of side products in crude products were observed than for similar syntheses in which cyclization was performed in solution (Pawlak et al.,1997; Filip et al.,2003). The increased amount of side-products may be due to formation of a carbonyl bridge between two peptide chains. In cyclization in solution, this problem was overcome by strong dilution of the reaction mixture. Fortunately, using semi-preparative HPLC, we were able to isolate the desired products. All samples for biological studies and NMR measurements were free of any contamination, as judged from analytical HPLC and MS spectra. The chemical formulas of the peptides are presented in Fig. 1. In vitro opioid activity profiles of the peptides were determined using the GPI and MVD assays (Table 1). The peptides were found to be agonists both assays. The activities of the peptides varied depending on the size of the ring. The most active was peptide 1 in which an 18-membered ring was formed by incorporation of side-chain amino groups of d-Lys and Dap. It should be recalled that among amides of cyclic enkephalin the most active peptide contained the same ring (Pawlak et al. 2001). It can be seen that the activity of the peptides is high in the MVD assay and relatively lower in the GPI assay.

Since peptide 1 is the most δ-selective agonist in this series and deserves to be studied in vivo, it is reasonable to compare (see Table 2) the selectivity of all peptides studied earlier containing the cyclic structure formed by incorporation of side chain amino groups of d-Lys and l-Dap: the GPI/MVD ratios of amide of cyclo[Nε, Nδ -carbonyl-d-Lys2, Dap5 ]enkephalin and N-(ureidoethyl) amide of cyclo[Nε, Nδ -carbonyl-d-Lys2, Dap5 ]enkephalin were 0.33 (Pawlak et al, 1997) and 1.09 (Ciszewska et al, 2009), respectively, and in the case of the hybrid peptide 1 it was 6.97. This shift in selectivity in favor of δ receptors seems to be important in view of our recent finding (Kotlińska et al, 2009) that even amide of cyclo[Nε,Nδ -carbonyl-d-Lys2, Dap5 ]enkephalin, which is highly potent both in GPI and MVD assays, in vivo studies, with the use of selective opioid receptor antagonists, induced antinociception predominantly through opioid δ receptors.

Table 2. GPI/MVD ratio of enkephalin N-(ureidoethyl)amides(Ciszewska et al., 2009) and enkephalin/deltorphin hybrid N-(ureidoethyl)amides (this work).

Amino acids in positions 2 and 4 Enkephalin ureido-ethylamides Enkephalin/deltorphin hybrid ureidoethyl-amides
d-Lys, Dap 1.97/1.81 (= 1.09) 12.9/1.85 (= 6.97)
d-Lys, Dab 5.55/6.00 (= 0.92) 47.5/16.9 (= 2.81)
d-Lys, Orn 18.1/22.7 (= 0.79) 30.8/4.18 (= 7.36)
d-Orn, Dap 11.3/14.1 (= 0.80) 76.9/18.5 (= 4.16)
d-Orn, Dab 3.36/11.6 (= 0.29) 72.1/20.5 (= 3.53)
d-Orn, Lys 16.1/28.2 (= 0.57) 71.3/14.5 (= 4.92)

Mean value 9.40/14.1 (= 0.64) 51.9/12.6 (= 4.12)

These results clearly indicate that the increase of selectivity in favor of the δ receptor was achieved by a decrease in the affinity of these peptides for the μ receptor, whereas the δ receptor affinity was more or less unchanged. These results show that in this case the role of the address is different from what was expected on the basis of the message-address concept, insofar as addition of the address sequence did not increase the affinity for the δ receptor.

In our previous studies on deltorphin analogs we observed that elongation of the cyclic N-terminal segment (Filip et al., 2003; Zieleniak et al., 2008) with Val-Val-Gly, to obtain the full sequence of deltorphin, also resulted in an increase in selectivity in favor of the δ receptor. This was not only due to a decrease in activity at the μ receptor but also to an increase of the activity at the δ receptor.

It seems that at least in the cases presented in this work, the use of the term modulator rather than the commonly used term address may be more appropriate for the description of a peptide segment which upon addition to a biologically active peptide changes the receptor selectivity.

For a better description and understanding of the biological results at the molecular level the NMR/EDMC method was employed (Sidor et al., 1999). Temperature coefficients of amide protons obtained from NMR spectra of peptides 2, 3 and 4 are rather high (Table 3S). Relatively lower values were observed only for amide protons of the Daa5 residues, similar to what was observed for other opioid peptide analogs (Ciszewska et al., 2009; Zieleniak et al., 2008). This suggests that the amide protons are not engaged in intramolecular hydrogen bonding.

The ensembles of conformations generated and accepted in the EDMC procedure for each peptide are listed in Table 7S in Supplementary Materials. They were clustered into families using an energy threshold of 20 kcal/mol and an r.m.s.d. of 0.15 Å as separation criteria. Numbers of the families are also given in Table 7S For representatives of each family, NOESY spectra were generated assuming a mixing time of 0.2 s and applying a correlation time of 0.45 ns. The Marquardt convergence criterion value of 10–5 was used in calculations of statistical weights of conformations. The conformers obtained for peptides 2, 3 and 4 using the EDMC/NMR method are presented as their VMD (Humphrey et al., 1996) drawings in Fig. 2 and corresponding selected torsional angles are listed in Table 3.

Figure 2. VMD drawings (Humphrey et al., 1996) of the most populated (above 3 %) EDMC/NMR calculated conformations of peptides 2, 3 and 4.

Figure 2

The structures are superimposed using C and N atoms of the main ring

Table 3. Parameters for the most populated (populations above 3 %) conformations of peptides 2, 3 and 4 found in water.

χ1(1)a ψ(1)a φ(2)a ψ(2)a φ(3)a ψ(3)a φ(4)a χ1(4)a rb Ec popd
2(D-Lys2, Dab5)
2–1 −67 −39 148 −135 158 −163 −99 −61 12.6 0.0 22.4
2–2 −64 151 151 −133 136 −112 −153 172 17.4 −0.5 19.7
2–3 170 −58 148 −136 173 172 −86 −57 7.5 −0.7 14.3
2–4 −66 −36 148 −132 136 −113 −152 174 16.7 0.7 9.1
2-5 171 −51 135 −88 −76 72 −162 166 7.2 1.1 6.0
2–6 −59 12 96 −133 103 −34 −62 177 15.3 0.7 5.4
2–7 176 −46 150 −137 162 −97 −152 175 13.4 −0.2 4.8
2–8 −65 153 151 −134 126 −108 −155 171 17.1 −0.4 4.6
2–9 175 −46 150 −141 117 −172 −87 −178 14.3 0.9 3.1
Σ = 89.4
3 (D-Lys2, Orn5)
3–1 −174 154 74 47 −161 49 −102 −50 5.4 0.0 19.2
3–2 178 140 152 −140 −174 −153 −61 178 15.2 −2.6 14.1
3–3 177 115 153 −168 161 −146 −62 176 14.6 −1.7 13.0
3–4 −178 158 86 34 −124 −58 −93 −60 9.9 2.1 12.6
3–5 −170 149 82 −78 −62 −40 −68 179 9.2 3.5 11.2
3–6 −172 −29 78 27 −165 41 −73 −173 9.1 −0.3 7.1
3–7 −172 147 81 −75 −76 59 −177 165 7.9 −0.3 5.5
3–8 179 136 78 −147 81 −77 −55 175 12.5 −1.2 4.9
Σ = 87.6
4 (D-Orn2, Dap5)
4–1 −176 155 78 39 −160 46 −142 −60 7.7 0.0 16.1
4–2 −176 156 79 34 −139 81 −172 165 9.5 1.5 15.6
4–3 −174 146 73 32 −75 −32 −157 53 9.8 2.0 9.3
4-4 −174 158 86 41 −149 53 −140 −53 6.2 1.3 8.1
4–5 −175 155 76 40 −159 49 −141 40 5.4 1.2 8.1
4–6 −176 154 71 47 −157 45 −148 41 5.6 −0.2 8.1
4–7 −177 152 75 −162 87 −63 −56 174 11.7 0.6 6.8
4–8 −175 154 70 44 −152 45 −145 41 5.5 0.9 6.8
4–9 178 152 86 −133 114 −41 −62 178 12.0 2.9 5.9
4–10 −176 142 77 −152 111 −58 −64 −61 10.3 1.9 4.5
4–11 177 −44 74 37 −147 32 −98 −56 5.3 2.5 4.5
4–12 −176 153 74 54 −178 −38 −53 66 5.7 0.3 4.3
Σ = 90.0
a

Values of selected torsional angles for the Tyr-Phe “spacer”

b

distance between tyrosine and phenylalanine ring centers (r in Å)

c

relative calculated energy (E in kcal/mol)

d

relative populations of conformers (pop in %)

Inspection of the data presented in Table 3 reveals a large diversity of conformations of the peptides. Their geometries and populations differ significantly. In each case several well populated conformers with substantially varying distances between the aromatic rings of Phe1 and Tyr4 were calculated.

A comparison of the r.m.s.d. values calculated for conformers of these peptides and those obtained earlier for their shorter analogs (Ciszewska et al., 2009) indicates that the flexibility of the main rings is similar. The r.m.s.d. values were calculated using the carbon and nitrogen atoms of the main ring for 2, 3 and 4, yielding values of 0.68 Å, 0.80 Å and 0.46 Å, respectively, while the r.m.s.d. values reported for the shorter analogs were 0.75 Å, 0.74 Å and 0.51 Å, respectively. The r.m.s.d. values calculated after superposition in the peptide segment situated between the Tyr and Phe residues were 0.40 for 2, 0.45 for 3 and 0.27 Å for 4, which suggests decreased conformational diversity as compared with the whole ring. This propensity of the main ring is common for all types of the peptides analyzed by us earlier (Pawlak et al., 2001; Filip et al., 2005; Ciszewska et al., 2009).

The r.m.s.d. values calculated using all heavy atoms of all residues were 3.73 for 2, 2.73 for 3 and 2.83 Å for 4, which indicates a rather high conformational freedom of these peptides. This opens the possibility for additional intramolecular interactions. In fact, for all three peptides NOE contacts were observed between the ring protons of Phe4 and the CH3 groups of Val6. In addition, visual inspection of the VMD drawings of all calculated conformers shown in Fig. 2 reveals that the conformers of peptide 3 are relatively compact. This is in agreement with the NOE contacts between γCH3 (Val7) and ring (Tyr1) protons observed in the spectra of this peptide. It may also be noticed that for a large set of conformers of peptide 4 their C-terminal segments are directed towards their main ring. These close contacts indicate the presence of additional intramolecular interactions involving aromatic rings and in consequence may have an impact on the possibility of interactions between these rings.

In spite of the differences in distances between the aromatic rings it seems reasonable to assume that these conformations are flexible enough to adopt a conformation permitting interaction with the opioid receptor to induce a biological effect. The similar results for enkephalin-deltorphin hybrids and corresponding enkephalins in the MVD assay support this suggestion.

Conclusions

The synthesis of N-(ureidoethyl)amides of cyclic enkephalin-deltorphin hybrids was carried out using the method described earlier (Ciszewska et al.,2009). The peptides differed from cyclic enkephalin N-(ureidoethyl) amides reported earlier in that the amino acid chain was elongated C-terminally with the Val-Val-Gly sequence, the address sequence of deltorphin responsible for its high affinity for δ receptors (Charpentier et al.,1991).

It should be noted that the increased selectivity for δ receptors was mainly result of decreased activity for μ receptors. The activity in the MVD assay of N-ureido-ethylamides of cyclic enkephalins and enkephalin-deltorphin hybrids was similar. Since, in most cases, increased selectivity towards δ receptors was obtained as a result of a decrease of the affinity for μ receptors, but not an increase towards δ receptors, it would be reasonable to use the term modulator instead of address for a sequence that changes the receptor selectivity ratio.

Statistical weights of conformations for three of the six peptides sufficiently soluble in water to permit the recording of NMR spectra were obtained in a global conformational search using the EDMC method in combination with experimental NOE parameters. NOE contacts for all three peptides between their ring protons of Phe4 and the CH3 groups of Val6 and for peptide 3 between its ring protons of Tyr1 and the γCH3 group of Val7 were observed. This finding indicates that a sequence added to a message, or to a sequence containing the message, is able to introduce additional intra-molecular interactions between the message and the rest of the molecule. In the present studies the additional peptide chain interacting with the message restricted by ring formation had no effect on the results of the MVD assay.

Supplementary Material

1

Acknowledgments

This work was supported by the Ministry of Science and Higher Education, Poland (3T09A 023 28) and the U.S. National Institutes of Health (DA-004443).

Abbreviations

CLUST

a program for cluster analysis

EDMC

Electrostatically Driven Monte Carlo

gHSQC

gradient Heteronuclear Single Quantum Coherence Spectroscopy

MBHA

4-methylben-zhydrylamine

MORASS

Multiple Overhauser Relaxation Analysis and Simulation

ROESY

Rotating Frame Overhauser Enhancement Spectroscopy

R.m.s.d.

Root mean square deviation

Footnotes

Supplementary Materials available at: www.actabp.pl

References

  1. Akiyama K, Gee KW, Mosberg HI, Hruby VJ, Yamamura HI. Characterization of [3H][2-D-penicillamine, 5-D-penocillamine]-enkephalin binding to δ opiate receptors in the rat brain and neuroblastoma-glioma hybrid cell line (NG 108-15) Proc Natl Acad Sci USA. 1985;82:2543–2547. doi: 10.1073/pnas.82.8.2543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aue WP, Bartholdi E, Ernst RR. Two-dimensional spectroscopy. Application to nuclear magnetic resonance. J Chem Phys. 1976;64:2229–2246. [Google Scholar]
  3. Bax A, Davis DG. Practical aspects of two-dimensional transverse NOE spectroscopy. J Magn Reson. 1985a;63:207–213. [Google Scholar]
  4. Bax A, Freeman R. Enhanced NMR resolution by restricting the effective sample volume. J Magn Reson. 1985b;65:355–360. [Google Scholar]
  5. Bothner-By AA, Stephens RL, Lee J-M, Warren CD, Jeanloz RW. Structure determination of tetrasaccharide: transient nuclear Overhauser effects in the rotating frame. J Am Chem Soc. 1984;106:811–813. [Google Scholar]
  6. Braunschweiler L, Ernst RR. Coherence transfer by isotropic mixing: application to proton correlation spectroscopy. J Magn Reson. 1983;53:521–528. [Google Scholar]
  7. Charpentier S, Sagan S, Delfour A, Nicolas P. Derenkephalin and deltorphin I reveal similarities within ligand-binding domains of μ- and δ-opioid receptors and an additional address subside on the δ-receptor. Biochem Biophys Res Commun. 1991;179:1161–1168. doi: 10.1016/0006-291x(91)91693-7. [DOI] [PubMed] [Google Scholar]
  8. Cheng PY, Wu D, Soong Y, McCabe S, Decena JA, Szeto HH. Role of mu 1- and delta-opioid receptors in modulation of fetal EEG and respiratory activity. Am J Physiol. 1993;265:433–438. doi: 10.1152/ajpregu.1993.265.2.R433. [DOI] [PubMed] [Google Scholar]
  9. Ciszewska M, Kwasiborska M, Nowakowski M, Oleszczuk M, Wójcik J, Chung NN, Schiller PW, Izdebski J. N-(ureidoethyl)amides of cyclic enkephalin analogs. J Peptide Sci. 2009;15:312–318. doi: 10.1002/psc.1118. [DOI] [PubMed] [Google Scholar]
  10. Cohen JH, Abdel-Magid AF, Almond HR, jr, Maryanoff CA. Stereoselective synthesis of beta-aryl-beta-amino esters. Tetrahedron Lett. 2002;43:1977–1981. [Google Scholar]
  11. Cowan A, Zhu XZ, Mosberg HI, Omnaas JR, Porrwca F. Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther. 1988;246:950–955. [PubMed] [Google Scholar]
  12. Davies J. The cyclization of peptides and depsipeptides. J Peptide Sci. 2003;9:471–501. doi: 10.1002/psc.491. [DOI] [PubMed] [Google Scholar]
  13. DiMaio J, Schiller PW. A cyclic enkephalin analog with high in vitro opiate activity. Proc Natl Acad Sci USA. 1980;77:7162–7166. doi: 10.1073/pnas.77.12.7162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Filip K, Oleszczuk M, Pawlak D, Wójcik J, Chung NN, Schiller PW, Izdebski J. Potent side-chain to side-chain cyclized dermorphin analogues containing a carbonyl bridge. J Peptide Sci. 2003;9:649–657. doi: 10.1002/psc.510. [DOI] [PubMed] [Google Scholar]
  15. Filip K, Oleszczuk M, Wójcik J, Chung NN, Schiller PW, Pawlak D, Zieleniak A, Parcińska A, Witkowska E, Izdebski J. Cyclic enkephalin and endorphin analogues containing a carbonyl bridge. J Peptide Sci. 2005;11:347–352. doi: 10.1002/psc.613. [DOI] [PubMed] [Google Scholar]
  16. Gutkowska J, Jankowski M, Pawlak D, Makaddam-Daher S, Izdebski J. The cardiovascular and renal effects of highly potent μ-opioid receptor agonist, cyclo[Nε,Nβ-carbonyl-d-Lys2, Dap5] enkephalinamide. Eur J Pharmacol. 2004;496:167–174. doi: 10.1016/j.ejphar.2004.06.007. [DOI] [PubMed] [Google Scholar]
  17. Hendrson G, Hughes J, Kosterlitz H. A new example of morphine sensitive neuroeffector junction. Br J Pharmacol. 1972;46:764–766. doi: 10.1111/j.1476-5381.1972.tb06901.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Humphrey W, Dalke A, Schulten K. VMD — visual molecular dynamics. J Mol Graphics. 1996;14:33–38. doi: 10.1016/0263-7855(96)00018-5. [DOI] [PubMed] [Google Scholar]
  19. Janecka A, Kruszynski R. Conformationally restricted peptides as tools in opioid receptor studies. Curr Med Chem. 2005;12:471–481. doi: 10.2174/0929867053362983. [DOI] [PubMed] [Google Scholar]
  20. Kay LE, Keifer P, Saarinen T. Pure absorption gradient-enhanced heteronuclear single quentum correlation spectroscopy with improved sensitivity. J Am Chem Soc. 1992;114:10663–10665. [Google Scholar]
  21. Kotlińska J, Bochenski M, Lagowska-Lenard M, Gibula-Bruzda E, Witkowska E, Izdebski J. Enkephalin derivative, cyclo[Nε,Nβ -carbonyl-d-Lys2, Dap5]enkephalinamide (CUENK6), induces a highly potent antinociception in rats. Neuropeptides. 2009;43:221–228. doi: 10.1016/j.npep.2009.03.003. [DOI] [PubMed] [Google Scholar]
  22. Li Z, Scheraga HA. Monte Carlo-minimization approach to the multiple-minima problem in protein folding. Proc Natl Acad Sci USA. 1987;84:6611–6615. doi: 10.1073/pnas.84.19.6611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Liwo A, Tempczyk A, Oldziej S, Shenderowicz MD, Hruby VJ, Talluri S, Ciarkowski J, Kasprzykowski F, Lankiewicz L, Grzonka Z. Exploration of conformational space of oxytocyn and arginine-vaso-pressin using the electrostatically driven Monte Carlo and Molecular Dynamics methods. Biopolymers. 1996;38:157–175. doi: 10.1002/(sici)1097-0282(199602)38:2<157::aid-bip3>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  24. Marquard DW. An algorithm for least-squares estimation of nonlinear parameters. J Soc Indust Appl Math. 1963;11:431–441. [Google Scholar]
  25. Masman MF, Rodriguez AM, Svetaz L, Zacchino SA, Somlai C, Csizmadia IG, Penke B, Enriza RD. Synthesis and conformation-al analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties. Bioorgan Med Chem. 2006;14:7604–7614. doi: 10.1016/j.bmc.2006.07.007. [DOI] [PubMed] [Google Scholar]
  26. Masman MP, Somlai C, Garibotto FM, Rodriguez AM, de la Iglesia A, Zacchino SA, Penke B, Enriza RD. Structure-antifungal relationship of His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 and analogues. Bioorgan Med Chem. 2008;16:4347–4358. doi: 10.1016/j.bmc.2008.02.072. [DOI] [PubMed] [Google Scholar]
  27. Meadows RP, Post CB, Luxon BA, Gorenstein DG. MORASS 2.1. W.Lafayette: Pardue University; 1994. [Google Scholar]
  28. Misicka A, Lipkowski A, Horvath R, Davis P, Porreca F, Yamamura HI, Hruby VJ. Int J Peptide Protein Res. 1994;44:80–84. doi: 10.1111/j.1399-3011.1994.tb00407.x. [DOI] [PubMed] [Google Scholar]
  29. Nemethy G, Gibson KD, Palmer KA, Yoon CN, Paterlini G, Zagari A, Rumsey S, Sheraga HA. Energy parameters in polypeptides. 10. Improved geometrical parameters and nonbonded interactions for use in the ECEPP/3 algoritm, with application to praline-containing peptides. J Phys Chem. 1992;96:6472–6484. [Google Scholar]
  30. Palmer AG, III, Cavanagh J, Wright PE, Rance M. Sensitivity improvement in proton detected heteronuclear correlation experiments. J Magn Reson. 1991;93:151–170. [Google Scholar]
  31. Paton WDM. The action of morphine and related substances on contraction on acylcholine output of coaxially stimulated guinea pig ileum. Br J Pharmacol. 1957;12:119–127. doi: 10.1111/j.1476-5381.1957.tb01373.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pawlak D, Chung NN, Schiller PW, Izdebski J. Synthesis of novel side-chain to side-chain cyclized enkephalin analogues containing a carbonyl bridge. J Peptide Sci. 1997;3:277–281. doi: 10.1002/(sici)1099-1387(199707)3:4<277::aid-psc107>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  33. Pawlak D, Oleszczuk M, Wójcik J, Pachulska M, Chung NN, Schiller PW, Izdebski J. Highly potent side chain to side chain cyclized enkephalin analogs containing a carbonyl bridge: synthesis, biology and conformation. J Peptide Sci. 2001;7:128–140. doi: 10.1002/psc.303. [DOI] [PubMed] [Google Scholar]
  34. Su YF, McNutt RW, Chung KJ. Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther. 1998;287:815–823. [PubMed] [Google Scholar]
  35. Schiller PW, Lipton A, Horrobin DF, Bodanszky M. Unsulfated C-terminal 7-peptide of cholecystokinin: a new ligant of the opiate receptor. Biochem Biophys Res Commun. 1978;85:1332–1338. doi: 10.1016/0006-291x(78)91149-x. [DOI] [PubMed] [Google Scholar]
  36. Sidor M, Wójcik J, Pawlak D, Izdebski J. Conformational analysis of novel cyclic enkephalin analogue using NMR and EDMC calculations. Acta Biochim Pol. 1999;46:641–650. [PubMed] [Google Scholar]
  37. Spath H. Cluster Analysis Algorithms. Halsted Press; New York: 1980. [Google Scholar]
  38. Vila J, Wiliams RI, Vasquez M, Scheraga HA. Empirical salvation models can be used to differentiate native from near-native conformations of bovine pancreatic trypsin inhibitor. Proteins: Struct Fun Genet. 1991;10:199–218. doi: 10.1002/prot.340100305. [DOI] [PubMed] [Google Scholar]
  39. Waterfield AA, Leslie FM, Lord JAH, Ling N. Opioid activities of fragments of β-endorphin and of its leucine65-analogue 5. Eur J Pharmacol. 1979;58:11–18. doi: 10.1016/0014-2999(79)90334-0. [DOI] [PubMed] [Google Scholar]
  40. Wishart DS, Bigam CG, Yao J, Abildgaard F, Dyson HJ, Oldfield E, Markley JL, Sykes BD. 1H, 13C, 15N chemical shift referencing in biomolecular NMR. J Biomol NMR. 1995;6:135–140. doi: 10.1007/BF00211777. [DOI] [PubMed] [Google Scholar]
  41. Wiszniewska A, Kunce D, Chung NN, Schiller PW, Izdebski J. p-Nitrophenoxycarbonyl derivatives of Boc-protected diaminoal-kanes in the synthesis of enkephalin peptidomimetics. J Peptide Sci. 2005;11:579–583. doi: 10.1002/psc.650. www.cgl.ucaf.edu/home/sparky, www.actabp.pl/Paper in Press. [DOI] [PubMed]
  42. Zieleniak A, Rodziewicz-Motowidło S, Rusak Ł, Chumg NN, Czaplewski C, Witkowska E, Schiller PW, Ciarkowski J, Izdebski J. Deltorphin analogs restricted via a urea structure and opioid activity. J Peptide Sci. 2008;14:830–837. doi: 10.1007/978-0-387-73657-0_212. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES